{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:54:11Z","timestamp":1771037651903,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.neurot.2024.e00484","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T17:09:06Z","timestamp":1732122546000},"page":"e00484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intrathecal administration of Anti-Nogo-A antibody in macaque monkeys: Pharmacokinetics, tissue penetration and target interaction"],"prefix":"10.1016","volume":"22","author":[{"given":"Pascal B.","family":"Kunz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannik","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Machacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Klisic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.neurot.2024.e00484_bib1","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00484_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00484_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/mi.3.2.90","article-title":"Blood-brain barrier drug targeting: the future of brain drug development","volume":"3","author":"Pardridge","year":"2003","journal-title":"Mol Interv"},{"issue":"7618","key":"10.1016\/j.neurot.2024.e00484_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"Maier M., et\u00a0al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00484_bib7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson\u2019s disease","volume":"387","author":"Lang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00484_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00484_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","article-title":"Antibody therapies in CNS diseases","volume":"120","author":"Freskg\u00e5rd","year":"2017","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00484_bib11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/NXI.0000000000000018","article-title":"Wattjes M.P., et\u00a0al. Randomized phase I trials of the safety\/tolerability of anti-LINGO-1 monoclonal antibody BIIB033","volume":"1","author":"Tran","year":"2014","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12987-018-0093-6","article-title":"Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration","volume":"15","author":"Wang","year":"2018","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00484_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.26503","article-title":"Phase 1 evaluation of elezanumab (Anti\u2013Repulsive guidance molecule A monoclonal antibody) in healthy and multiple sclerosis participants","volume":"93","author":"Kalluri","year":"2023","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00484_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00484_bib15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1021\/mp300474m","article-title":"Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS","volume":"10","author":"Papisov","year":"2013","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00484_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cpt.2531","article-title":"Translational approaches for brain delivery of biologics via cerebrospinal fluid","volume":"111","author":"Sadekar","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00484_bib17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of Rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00484_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1078-0432.CCR-13-0474","article-title":"Complement activation and intraventricular Rituximab distribution in recurrent central nervous system lymphoma","volume":"20","author":"Kadoch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2024.e00484_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.2188","article-title":"Antigen mass may influence trastuzumab concentrations in cerebrospinal fluid after intrathecal administration","volume":"110","author":"Le Tilly","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","article-title":"Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis","volume":"139","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"6\u20137","key":"10.1016\/j.neurot.2024.e00484_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1545968318776371","article-title":"First-in-Man intrathecal application of neurite growth-promoting anti-nogo-A antibodies in acute spinal cord injury","volume":"32","author":"Kucher","year":"2018","journal-title":"Neurorehabilitation Neural Repair"},{"key":"10.1016\/j.neurot.2024.e00484_bib23","article-title":"Safety and efficacy of intrathecal anti-Nogo-A antibody treatment in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","author":"Weidner","year":"2024","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00484_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1474-4422(23)00215-6","article-title":"Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial","volume":"22","author":"Maynard","year":"2023","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00484_bib25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrn2936","article-title":"Functions of Nogo proteins and their receptors in the nervous system","volume":"11","author":"Schwab","year":"2010","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00484_bib26","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1523\/JNEUROSCI.22-09-03553.2002","article-title":"Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions","volume":"22","author":"Huber","year":"2002","journal-title":"J\u00a0Neurosci"},{"issue":"13","key":"10.1016\/j.neurot.2024.e00484_bib27","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1523\/JNEUROSCI.22-13-05505.2002","article-title":"Localization of nogo-A and nogo-66 receptor proteins at sites of axon\u2013myelin and synaptic contact","volume":"22","author":"Wang","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00484_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.conb.2014.02.011","article-title":"Nogo limits neural plasticity and recovery from injury","volume":"27","author":"Schwab","year":"2014","journal-title":"Curr Opin Neurobiol"},{"issue":"1\u20132","key":"10.1016\/j.neurot.2024.e00484_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.mcn.2006.03.007","article-title":"Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A","volume":"32","author":"Weinmann","year":"2006","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00484_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1124\/dmd.121.000695","article-title":"Cynomolgus monkey as an emerging animal model to study drug transporters: in vitro, in vivo, in vitro-to-in vivo translation","volume":"50","author":"Shen","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.neurot.2024.e00484_bib31","first-page":"13","article-title":"European convention for the protection of vertebrate animals used for experimental and other scientific purposes. ETS No 123","year":"1986","journal-title":"Sect. Appendix A"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00484_bib32","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1177\/40.10.1527370","article-title":"Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains","volume":"40","author":"Adams","year":"1992","journal-title":"J\u00a0Histochem Cytochem"},{"issue":"13","key":"10.1016\/j.neurot.2024.e00484_bib33","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1523\/JNEUROSCI.23-13-05393.2003","article-title":"Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions","volume":"23","author":"Oertle","year":"2003","journal-title":"J\u00a0Neurosci"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00484_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/19420862.2018.1462429","article-title":"Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach","volume":"10","author":"Betts","year":"2018","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00484_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11537430-000000000-00000","article-title":"Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction","volume":"50","author":"Dong","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12967-020-02461-2","article-title":"Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system","volume":"18","author":"Sullivan","year":"2020","journal-title":"J\u00a0Transl Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00484_bib37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00484_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4161\/mabs.4.2.19364","article-title":"Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys","volume":"4","author":"Datta-Mannan","year":"2012","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00484_bib39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/neu.2011.1752","article-title":"Delayed anti-nogo-A antibody application after spinal cord injury shows progressive loss of responsiveness","volume":"29","author":"Gonzenbach","year":"2012","journal-title":"J\u00a0Neurotrauma"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00484_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1091581810361527","article-title":"A\u00a04-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys","volume":"29","author":"Braen","year":"2010","journal-title":"Int J Toxicol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00484_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10928-019-09641-8","article-title":"A\u00a0translational platform PBPK model for antibody disposition in the brain","volume":"46","author":"Chang","year":"2019","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00484_bib42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10928-021-09761-0","article-title":"A\u00a0physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration","volume":"48","author":"Monine","year":"2021","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.neurot.2024.e00484_bib43","doi-asserted-by":"crossref","first-page":"1130925","DOI":"10.3389\/fphys.2023.1130925","article-title":"A\u00a0mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides","volume":"14","author":"Linninger","year":"2023","journal-title":"Front Physiol"},{"key":"10.1016\/j.neurot.2024.e00484_bib44","first-page":"251","article-title":"Solute transport in the cerebrospinal fluid: physiology and practical implications. Nerv syst drug deliv","author":"Papisov","year":"2019","journal-title":"Elsevier"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00484_bib45","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1109\/TBME.2019.2930451","article-title":"In vivo intrathecal tracer dispersion in cynomolgus monkey validates wide biodistribution along neuraxis","volume":"67","author":"Tangen","year":"2020","journal-title":"IEEE Trans Biomed Eng"},{"key":"10.1016\/j.neurot.2024.e00484_bib46","series-title":"Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration","volume":"284","author":"Bergman","year":"1998"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00484_bib47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4161\/mabs.22189","article-title":"A\u00a0strategy for risk mitigation of antibodies with fast clearance","volume":"4","author":"H\u00f6tzel","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.neurot.2024.e00484_bib48","volume":"vol. 91","author":"Spera","year":"2023"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12987-022-00320-4","article-title":"Parasagittal dural space and cerebrospinal fluid (CSF) flow across the lifespan in healthy adults","volume":"19","author":"Hett","year":"2022","journal-title":"Fluids Barriers CNS"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00484_bib50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1471-4159.2002.00840.x","article-title":"Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier: expression of FcRn at the blood-brain barrier","volume":"81","author":"Schlachetzki","year":"2002","journal-title":"J\u00a0Neurochem"},{"issue":"30","key":"10.1016\/j.neurot.2024.e00484_bib52","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1073\/pnas.0402970101","article-title":"Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level","volume":"101","author":"Ober","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2024.e00484_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2013.08.035","article-title":"Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor","volume":"1534","author":"Cooper","year":"2013","journal-title":"FcRn. Brain Res"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2045-8118-11-26","article-title":"Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence","volume":"11","author":"Hladky","year":"2014","journal-title":"Fluids Barriers CNS"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00484_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12789","article-title":"The blood\u2013CSF\u2013brain route of neurological disease: the indirect pathway into the brain","volume":"48","author":"Cousins","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00484_bib56","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1113\/JP275105","article-title":"Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery","volume":"596","author":"Pizzo","year":"2018","journal-title":"J\u00a0Physiol"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00484_bib57","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1021\/mp300495e","article-title":"Diffusion of macromolecules in the brain: implications for drug delivery","volume":"10","author":"Wolak","year":"2013","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00484_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymthe.2006.02.018","article-title":"The \u201cperivascular pump\u201d driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain","volume":"14","author":"Hadaczek","year":"2006","journal-title":"Mol Ther"},{"issue":"147","key":"10.1016\/j.neurot.2024.e00484_bib59","article-title":"A\u00a0paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci Transl Med [Internet]"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00484_bib60","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","article-title":"The glymphatic system: a beginner\u2019s guide","volume":"40","author":"Jessen","year":"2015","journal-title":"Neurochem Res"},{"issue":"22","key":"10.1016\/j.neurot.2024.e00484_bib61","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1111\/bph.14021","article-title":"Widespread brain distribution and activity following i.c.v. infusion of anti-\u03b2-secretase (BACE1) in nonhuman primates: brain antibody distribution after i.c.v. delivery","volume":"174","author":"Yadav","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00484_bib62","doi-asserted-by":"crossref","first-page":"eaau9859","DOI":"10.1126\/sciadv.aau9859","article-title":"Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion","volume":"4","author":"Castle","year":"2018","journal-title":"Sci Adv"},{"issue":"6627","key":"10.1016\/j.neurot.2024.e00484_bib63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.adc8810","article-title":"A\u00a0mesothelium divides the subarachnoid space into functional compartments","volume":"379","author":"M\u00f8llg\u00e5rd","year":"2023","journal-title":"Science"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:09:13Z","timestamp":1762560553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1878747924001715"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00484","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrathecal administration of Anti-Nogo-A antibody in macaque monkeys: Pharmacokinetics, tissue penetration and target interaction","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00484"}}